Amgen Inc, listed on NASDAQ, is a leading independent biotechnology company.
The company operates and provides its service worldwide with more than 75 subsidiaries and 65 branches in total.
The US-based company manufactures fusion proteins, therapeutic proteins, peptibodies, oncolytic viral therapies, etc.
The company engages in the discovery, development, manufacturing and marketing of human therapeutics.
Some of the popular brands of Amgen are:
Neulasta®: Launched in 2002, it is used to reduce the chance of infection due to low white blood cell count.
ENBREL®: Used for treating adult patients having conditions such as rheumatoid arthritis, active psoriatic arthritis. It was launched in 1998.
EPOGEN®: Primarily marketed in the United States for dialysis patients.
KYPROLIS®: A proteasome inhibitor
XGEVA®: It was launched in 2010 and is marketed in Europe and the United States
Other products include Corlanor®, Nplate®, Prolia®, Repatha® and Vectibix®.
The company aims to treat cancers, kidney diseases,
inflammatory disorders, and other diseases using cellular biology and medicinal chemistry.
Amgen Inc conducts clinical trials and focuses on research and development activities.
Meanwhile, the firm has its business and provides services in more than 100 countries globally.
Amgen Inc., formerly known as Applied Molecular Genetics, was founded on April 8, 1980, by William K. (Bill) Bowes and associates. It is headquartered in Thousand Oaks, California.
The increase in global KYPROLIS® and Prolia® sales for 2020 was driven by higher unit demand, rise in net selling price and favorable changes in inventory, the company claims.
The company is listed on the New York Stock Exchange (NYSE) and trades under the ticker 'AMGN'. It is also among NASDAQ-100, Dow Jones Industrial Average (DJIA), S&P 500, and S&P 100 components.
It was also reportedly among Forbes Global 2000 rankings for 2021.
The product pipeline includes different therapeutic areas such as:
• metabolic disorders